Daratumumab, an anti-CD38 monoclonal antibody shows promise in refractory autoimmune diseases such as systemic lupus erythematosus, Sjögren’s syndrome, and ANCA-associated vasculitis. The gene discussed is CD38; the disease is anti-neutrophil cytoplasmic antibody-associated vasculitis.